Document is current

Article History

Received: 6 April 2024

Accepted: 4 October 2024

First Online: 9 October 2024

Declarations

:

: Approval was obtained from the ethics committee of the TU Dresden (approval number: BO-EK (COVID)-482102021). Because of the non-interventional nature of routine healthcare data no consent to participate was collected nor would be feasibly. Due to the aggregation of the data, no personal identification of the participants was possible at the analysis stage. This waiver for informed consent was confirmed by ethics committee of the Faculty of Medicine Carl Gustav Carus at the TU Dresden (IRB00001473).

: FT, FE, AV, ML, MS, GM, LR, CS, and JS and report institutional funding for this project from the German Federal Ministry of Health. Unrelated to this study, JS reports institutional grants for investigator-initiated research from the German Federal Joint Committee, German Ministry of Health, German Ministry of Research, European Union, German Federal State of Saxony, Novartis, Sanofi, ALK, and Pfizer. He participated in advisory board meetings as a paid consultant for Sanofi, Lilly, and ALK. JS serves the German Ministry of Health as a member of the German National Council for Health and Care. MB reports payment for data analysis which is presented in this paper from DAK-Gesundheit. Unrelated to this study, MB reports grants from German GBA, Pfizer, and Sanofi Pasteur and consulting fees from Janssen-Cilag. He participated in an advisory board for GSK. The other authors declare that they have no competing interest.